How much should a weight-loss clinic spend on Meta & Facebook ads in 2026?

Written by Karbon Agency, Editorial team · Updated September 26, 2026

Plan on $1,000–$4,000/mo in Meta ad spend, plus a flat agency retainer. LocaliQ publishes no weight-loss row; its nearest category, physicians and surgeons, averages $32.14 per Meta lead, so that buys roughly 31–124 leads a month. Every ad must target 18+, and anything promoting a prescription GLP-1 needs LegitScript certification on Meta and Google certification on search. On first-year programme fees, break-even runs about $36–$95 per lead.

What each budget buys a weight-loss clinic

Ad spend goes straight to Meta. The cost-per-lead column is the range published by the sources listed at the end of this page — not a promise, and not our own averages dressed up as an industry figure.

What the published benchmarks actually say

Three honest gaps. First, no neutral publisher has a weight-loss cost per lead on any channel: LocaliQ's Facebook tables, its general search table and its 16-specialty healthcare report all omit it, so this page uses physicians & surgeons ($32.14 Meta, $40.04 search) and names the proxy every time. LocaliQ disagrees with itself on medical search — $40.04 for physicians & surgeons in its general table, $62.80 for general practice and $66.02 for healthcare overall in its specialty report — and we show all three. Second, the only weight-loss-specific figures come from agencies selling to clinics; Practice Growth Co's are at least tied to LegitScript-certified accounts and stated as ranges. Third, patient value: the one documented programme price is the $138–$188 membership a telehealth firm advertised (per the FTC), while an agency reports $3,000–$8,000 of lifetime value. Those imply very different ceilings, and the break-even below uses the lower one.

What changes the number for a weight loss clinic

• Naming the drug moves you into a different policyMeta's health and wellness policy sends prescription weight-loss products to its drugs and pharmaceuticals policy, which requires online pharmacies and telehealth providers to be 'actively certified with LegitScript', allows only the US, Canada and New Zealand, and bars targeting under 18. Google requires its own certification to serve ads for prescription drug services and to keyword-target drug names. An ad about a physician-supervised programme runs under lighter rules than an ad that says tirzepatide.
• The compounding window closed in 2025The FDA resolved the tirzepatide shortage on December 19, 2024 and semaglutide on February 21, 2025, and ended enforcement discretion for 503A compounders on February 18 and April 22, 2025 respectively. On March 3, 2026 it warned 30 telehealth companies over claims implying compounded drugs were the same as approved ones. An ad built on a compounded-semaglutide price is now a regulatory risk, not just a policy one.
• Retention is the value of the leadPrime Therapeutics found 63% of people who started a high-potency obesity GLP-1 in early 2024 were still on it a year later, against 33% of 2021 starters — and only 8% of all obesity starters were still on therapy at three years. A clinic that keeps patients for a year is worth roughly twice one that loses two-thirds of them, and can afford twice the cost per lead.
• The manufacturer is now a competitor on priceLilly sells Zepbound direct for $299–$449 a month and Novo Nordisk sells Wegovy pens for $349 and tablets from $149. A patient can buy the drug without you, so a clinic's ads have to sell what the drug does not include: the physician, the labs, the follow-up and the accountability. KFF found 56% of GLP-1 users said the drugs were difficult to afford and 14% had stopped because of cost.
• Creative rules decide how fast an account scalesMeta requires weight-loss ads to target people 18 or older and prohibits statements of inferiority about appearance, close-ups pinching fat, and promises of specific outcomes within a set time without qualifiers. Its current page does not list before-and-after images among the weight-loss prohibitions — but the FTC's NextMed case alleged before-and-after photos of people who were not patients. Use only real, consented patients, with the timeframe stated.
• Demand is large and the competition is mostly your own doctorsGallup puts current GLP-1 use for weight loss at 11% of US adults in 2026, up from 3% in 2024. KFF found 76% of people who took one got it from one of their doctors, 17% from an online provider and 9% from a medical spa. The local clinic's competitor is less the national telehealth brand than the patient's own primary-care physician.

The only number that matters: your break-even cost per lead

Work backwards from what a patient pays you, not the drug. The one documented programme price is the $138–$188 monthly membership NextMed advertised, drug excluded (FTC, 2025). Prime Therapeutics found 33–63% of obesity GLP-1 starters still on therapy after a year, so counting only the patients who stay the whole year — a deliberate floor — a started patient is worth $546–$1,421 in first-year fees. If you are willing to spend a fifth of that to acquire them, you can afford $109–$284 per enrolled patient, which is almost exactly the $100–$300 Practice Growth Co reports paying. Its programme campaigns ran $38–$78 per lead against $100–$300 per enrolled patient, which is roughly three leads per enrolment. Divide by three and break-even is $36–$95 per lead. The physicians & surgeons Meta proxy, $32.14, sits just below that band; the $40.04 search proxy sits inside it. At the agency-reported $3,000–$8,000 lifetime value, every figure is several times higher — which is why retention, not the auction, is the number to fix first. Swap in your own programme fee and enrolment rate before you believe any of it.

How Karbon prices it

What we would actually recommend: start in the test tier advertising the programme — a physician-supervised consultation with labs and follow-up — rather than a drug name, because that keeps the ads under Meta's health and wellness rules instead of its prescription-drug rules and certification. Target 18+, show real patients with stated timeframes, and measure consult show rate and enrolment for six to eight weeks before judging cost per lead. Move to the growth tier once enrolment is near one lead in three, and add search on programme terms. Only run medication-name campaigns once you hold LegitScript and Google certification, and never price an ad on compounded semaglutide. Karbon charges a flat monthly retainer plus your ad spend.

Typical local-business agency retainers run $500–$3,000/mo depending on scope, channels, and how much strategy and creative is included — that fee is on top of your ad spend, which goes straight to the ad platforms.

• ✓Flat monthly retainer — not a percentage of your ad spend
• ✓Month-to-month — cancel with notice
• ✓Performance-based pricing available on request
• ✓No long-term lock-in

Frequently asked questions

Sources

Every figure above comes from one of these. Where two of them disagree we publish both numbers rather than picking the flattering one.

1. LocaliQ — Facebook Advertising Benchmarks, 2026 edition (Physicians & Surgeons and Health & Fitness rows) — September 23, 2026 (no weight-loss row; the page states no data-collection window)
2. LocaliQ — Search Advertising Benchmarks (Physicians & Surgeons row) — June 1, 2026
3. LocaliQ — Healthcare Search Advertising Benchmarks (16 specialties) — January 13, 2026 (data October 2024 – September 2025; no weight-loss or bariatric row)
4. Practice Growth Co — Google Ads for GLP-1 practices — May 18, 2026 (agency's own campaign data, 2025–2026, LegitScript-certified accounts)
5. Christoph Olivier Consulting — Weight loss clinic marketing — September 1, 2026 (marketing consultancy; page shows 'last reviewed September 2026')
6. Meta Transparency Center — Advertising Standards: Health and Wellness — July 23, 2026 (date of the latest changelog entry)
7. Meta Transparency Center — Advertising Standards: Drugs and Pharmaceuticals — February 26, 2025 (date of the latest changelog entry)
8. Google Ads policy — Prescription drug services certification — September 1, 2026 (undated help page, dated to the month it was read)
9. Google Ads policy — Restricted drug terms — September 1, 2026 (undated help page, dated to the month it was read)
10. FDA — FDA clarifies policies for compounders as national GLP-1 supply begins to stabilize — April 1, 2026 (content-current-as-of date)
11. FDA — FDA warns 30 telehealth companies against illegal marketing of compounded GLP-1s — March 3, 2026
12. FTC — FTC takes action against telemedicine firm NextMed — July 14, 2025
13. FTC — FTC approves final order against telehealth provider NextMed — December 3, 2025
14. Eli Lilly — Zepbound coverage and savings (self-pay prices) — August 1, 2026 (material CMAT-22250, dated 08/2026 — month and year only)
15. NovoCare Pharmacy — Wegovy self-pay prices — September 1, 2026 (undated page, dated to the month it was read)
16. Prime Therapeutics — Only 1 in 12 remain on a GLP-1 drug for obesity at three years — June 25, 2025 (pharmacy benefit manager's claims analysis; N = 5,780 (three-year) and 23,025 (one-year))
17. KFF — Poll: 1 in 8 adults say they are currently taking a GLP-1 drug — November 14, 2025 (fielded October 27 – November 2, 2025)
18. Gallup — GLP-1 usage reaches new high — September 8, 2026 (first published 2026-07-07; 5,065 US adults surveyed May 28 – June 5, 2026)

Published September 26, 2026 · Last reviewed September 26, 2026 by Karbon Agency. We change that date only when the content genuinely changes.

Want an exact number for your weight loss clinic?

Book a free call — we'll look at your market, your goals, and tell you what we'd actually spend. No pitch deck, no pressure.